Keywords: پادبَند یا ضد انعقاد; Anticoagulation; Atrial fibrillation; Rosendaal; Time in therapeutic range; Warfarin;
مقالات ISI پادبَند یا ضد انعقاد (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: پادبَند یا ضد انعقاد; Bridging; Anticoagulation; Peri-procedural; Interruption; Warfarin; Paediatric; Clinical outcomes; Moyamoya;
Keywords: پادبَند یا ضد انعقاد; Anticoagulation; Ovarian vein thrombosis; Pregnancy; Post-partum; Thrombophilia;
Keywords: پادبَند یا ضد انعقاد; Anticoagulación; Indicaciones; Sangrado; Manejo perioperatorio; Anticoagulation; Indications; Bleeding; Perioperative management;
Keywords: پادبَند یا ضد انعقاد; Plasmapheresis; Apheresis; Therapeutic plasma exchange; Anticoagulation;
Keywords: پادبَند یا ضد انعقاد; Acute coronary syndrome; Anticoagulation; Apixaban; Dual antiplatelet therapy; Triple antithrombotic therapy; Warfarin;
Keywords: پادبَند یا ضد انعقاد; Inguinal hernia; Inguinal herniorrhaphy; Postoperative hematoma; Groin hematoma; Anticoagulation
Keywords: پادبَند یا ضد انعقاد; Anticoagulation; Thromboprophylaxis; Venous thromboembolism; Outcome
Keywords: پادبَند یا ضد انعقاد; Free flap; Head and neck defect; Anticoagulation; Fluid management; Flap monitoring;
Keywords: پادبَند یا ضد انعقاد; AC; anticoagulation; APS; antiphospholipid antibody syndrome; CIs; confidence intervals; CVRN VTE; Cardiovascular Research Network Venous Thromboembolism; DVT; deep vein thrombosis; ICD-9; International Classification of Diseases 9th Revision; Ig; immunog
Keywords: پادبَند یا ضد انعقاد; Atrial fibrillation; Anticoagulation; Decision model; Personalized medicine;
Keywords: پادبَند یا ضد انعقاد; Fall; Trauma; Geriatric; Anticoagulation; Clopidogrel; Warfarin;
Keywords: پادبَند یا ضد انعقاد; Warfarin; Anticoagulation; Patient education; Knowledge assessment;
Keywords: پادبَند یا ضد انعقاد; Anticoagulation; deep vein thrombosis; DVT; heparin; venous thromboembolism
Keywords: پادبَند یا ضد انعقاد; Fibrilación auricular; Anticoagulación; Calidad; Tiempo en rango terapéutico; Atrial fibrillation; Anticoagulation; Quality; Time in therapeutic range;
Keywords: پادبَند یا ضد انعقاد; Fibrilación auricular; Anticoagulación; Atención primariaAtrial fibrillation; Anticoagulation; Primary care
Keywords: پادبَند یا ضد انعقاد; Hemodialysis; Anticoagulation; Cell activation; Tissue factor
Keywords: پادبَند یا ضد انعقاد; Anticoagulation; Cardiac biomarkers; Rate versus rhythm control; Telemetry; Weight and fluid management
Keywords: پادبَند یا ضد انعقاد; Heparin; Lovenox; Fondaparinux; Anticoagulation; Protamine sulfate;
Keywords: پادبَند یا ضد انعقاد; Septic; Cavernous sinus thrombosis; Cerebral venous thrombosis; Diagnosis; Management; Anticoagulation
Keywords: پادبَند یا ضد انعقاد; Low molecular weight heparin (LMWH); Rational design; Protamine sulfate; Anticoagulation; Anti-thrombus; Pharmacokinetic
Keywords: پادبَند یا ضد انعقاد; Atrial fibrillation; anticoagulation; interruption; heparin; bridging
Keywords: پادبَند یا ضد انعقاد; Anticoagulation; Reversal; Direct oral anticoagulants;
Keywords: پادبَند یا ضد انعقاد; Venous thromboembolism; Anticoagulation; Mortality
Keywords: پادبَند یا ضد انعقاد; Atrial fibrillation; New onset; Thromboembolism; Anticoagulation; Virchow
Keywords: پادبَند یا ضد انعقاد; Anticoagulation; Thrombosis; Embolism; Mortality
Keywords: پادبَند یا ضد انعقاد; Fucoidan; Laminin; Anticoagulation; Cardiovascular implants; Endothelial cells; Smooth muscle cells;
Keywords: پادبَند یا ضد انعقاد; Preterm infants; Thromboembolism; Anticoagulation
Keywords: پادبَند یا ضد انعقاد; Coronary intervention; Antithrombotic; Anticoagulation; Antiplatelet; Efficacy; Bleeding
Keywords: پادبَند یا ضد انعقاد; Anticoagulation; Venous thromboembolism; Haematological malignancies; Thrombocytopenia;
Keywords: پادبَند یا ضد انعقاد; Stroke; Atrial fibrillation; Cardioembolism; Anticoagulation;
Keywords: پادبَند یا ضد انعقاد; Anticoagulation; Novel oral anticoagulants; Rivaroxaban; Apixaban; Edoxaban; Dabigatran
Keywords: پادبَند یا ضد انعقاد; Carthamus tinctorius; Platelet aggregation; Anticoagulation; Antioxidant; Rats ovarian granulosa cell proliferation
Keywords: پادبَند یا ضد انعقاد; Antithrombotics; Anticoagulation; Percutaneous coronary intervention; Acute coronary syndrome; Stable coronary artery disease;
Keywords: پادبَند یا ضد انعقاد; intermittent pneumatic compression devices; venous thromboembolism prophylaxis; anticoagulation; joint arthroplasty; surgery
Keywords: پادبَند یا ضد انعقاد; Anticoagulation; Atrial fibrillation; Silent cerebral ischemia; Stroke;
Keywords: پادبَند یا ضد انعقاد; Anticoagulação; Novos anticoagulantes orais; Terapêutica antiagregante; Farmacologia; Anticoagulation; New Oral Anticoagulants; AntiâPlatelet therapy; Pharmacology;
Keywords: پادبَند یا ضد انعقاد; Heart failure; Stroke; Anticoagulation; Warfarin; Prevention;
Keywords: پادبَند یا ضد انعقاد; Hydrogel thin layers; Antifouling; Anticoagulation; Anti-bacterial; Poly(ether sulfone); Sulfobetaine methacrylate; Sodium allysulfonate; Methyl acryloyloxygen ethyl trimethyl ammonium chloride; In situ crosslinking polymerization; Surface attaching;
Keywords: پادبَند یا ضد انعقاد; Catastrophic antiphospholipid syndrome; Therapeutics; Anticoagulation; Corticoids; Plasma exchange; Intravenous immunoglobulins; Rituximab; Eculizumab; Sirolimus; Review;
Keywords: پادبَند یا ضد انعقاد; anticoagulation; antiplatelet; bleeding; coronary interventionACS, acute coronary syndrome(s); AF, atrial fibrillation; BMS, bare-metal stent(s); CAD, coronary artery disease; CI, confidence interval; DAPT, dual-antiplatelet therapy; DES, drug-eluting ste
Keywords: پادبَند یا ضد انعقاد; Anticoagulation; Nori; Porphyra; Peptide; Purification; Haemostasis;
Keywords: پادبَند یا ضد انعقاد; anticoagulation; emergency medicine; rivaroxaban; venous thromboembolism;
Keywords: پادبَند یا ضد انعقاد; Cirrhosis; Acute liver failure; Thrombocytopenia; Coagulopathy; Thrombosis; Anticoagulation;
Keywords: پادبَند یا ضد انعقاد; anticoagulation; bleeding risk; stroke prevention; AF; atrial fibrillation; b.i.d.; twice daily; CKD; chronic kidney disease; ESRD; end-stage renal disease; FDA; Food and Drug Administration; NOAC; non-vitamin K antagonist oral anticoagulant; TTR; time i
Keywords: پادبَند یا ضد انعقاد; Hemostasis; Blood transfusion; New oral anticoagulants; Anticoagulation; Quality;
Keywords: پادبَند یا ضد انعقاد; pulmonary hypertension; vitamin K antagonists; survival; safety; anticoagulation; warfarin; efficacy;
Keywords: پادبَند یا ضد انعقاد; myocardial infarction; pregnancy; prosthetic valves; valvular heart disease; AC; anticoagulation; BPHV; bioprosthetic heart valve; CHD; congenital heart disease; HF; heart failure; LMWH; low molecular weight heparin; MPHV; mechanical prosthetic heart val
Keywords: پادبَند یا ضد انعقاد; Multimorbidity; Atrial fibrillation; Anticoagulation; Warfarin; New oral anticoagulants; Polypharmacy; Bleeding risk;
Keywords: پادبَند یا ضد انعقاد; Venous thromboembolism; Pulmonary embolism; Deep venous thrombosis; Thrombophilia; Anticoagulation;